SMS Pharmaceuticals Limited (BOM:532815)
India
· Delayed Price · Currency is INR 240.75
-1.60 (-0.66%)
At close: Apr 25, 2025
SMS Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Operating Revenue | 7,804 | 7,093 | 5,221 | 5,199 | 5,632 | 4,119 | Upgrade
|
| Other Revenue | - | - | - | - | - | 23.57 | Upgrade
|
| Revenue | 7,804 | 7,093 | 5,221 | 5,199 | 5,632 | 4,143 | Upgrade
|
| Revenue Growth (YoY) | 27.32% | 35.86% | 0.42% | -7.69% | 35.93% | -11.24% | Upgrade
|
| Cost of Revenue | 5,333 | 4,983 | 3,900 | 3,309 | 3,797 | 2,804 | Upgrade
|
| Gross Profit | 2,471 | 2,109 | 1,321 | 1,890 | 1,835 | 1,339 | Upgrade
|
| Selling, General & Admin | 752.34 | 658.08 | 547.63 | 515.16 | 414.94 | 410.15 | Upgrade
|
| Other Operating Expenses | 391.5 | 276.02 | 224.85 | 222.38 | 202.34 | 98.02 | Upgrade
|
| Operating Expenses | 1,480 | 1,249 | 1,094 | 1,059 | 840.09 | 728.84 | Upgrade
|
| Operating Income | 990.95 | 860.1 | 226.98 | 830.73 | 994.62 | 609.75 | Upgrade
|
| Interest Expense | -182.46 | -226.18 | -209.94 | -181.57 | -102.54 | -111.93 | Upgrade
|
| Interest & Investment Income | 7.58 | 7.58 | 7.75 | 5.6 | 3.14 | 3.52 | Upgrade
|
| Earnings From Equity Investments | 27.31 | 6.26 | -109.43 | -56.61 | 15.62 | -11.15 | Upgrade
|
| Currency Exchange Gain (Loss) | 28.98 | 28.98 | 39.05 | 25.8 | 5.71 | 17.96 | Upgrade
|
| Other Non Operating Income (Expenses) | 10.08 | -9.78 | -9.8 | 4.47 | 10.34 | -11.22 | Upgrade
|
| EBT Excluding Unusual Items | 882.44 | 666.96 | -55.4 | 628.42 | 926.9 | 496.92 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.37 | 0.37 | -0.54 | -0.04 | -0.08 | -0.51 | Upgrade
|
| Pretax Income | 882.82 | 667.33 | -55.94 | 628.38 | 926.82 | 496.41 | Upgrade
|
| Income Tax Expense | 221.83 | 169.07 | 14.65 | 6.18 | 301.55 | 180.67 | Upgrade
|
| Net Income | 660.99 | 498.26 | -70.59 | 622.2 | 625.27 | 315.74 | Upgrade
|
| Net Income to Common | 660.99 | 498.26 | -70.59 | 622.2 | 625.27 | 315.74 | Upgrade
|
| Net Income Growth | 83.31% | - | - | -0.49% | 98.04% | -21.16% | Upgrade
|
| Shares Outstanding (Basic) | 85 | 85 | 85 | 85 | 85 | 85 | Upgrade
|
| Shares Outstanding (Diluted) | 85 | 85 | 85 | 85 | 85 | 85 | Upgrade
|
| Shares Change (YoY) | -0.31% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 7.82 | 5.89 | -0.83 | 7.35 | 7.39 | 3.73 | Upgrade
|
| EPS (Diluted) | 7.82 | 5.89 | -0.83 | 7.35 | 7.39 | 3.73 | Upgrade
|
| EPS Growth | 83.88% | - | - | -0.49% | 98.04% | -21.16% | Upgrade
|
| Free Cash Flow | - | -20.35 | -74.71 | 178.12 | -612.96 | -30.22 | Upgrade
|
| Free Cash Flow Per Share | - | -0.24 | -0.88 | 2.10 | -7.24 | -0.36 | Upgrade
|
| Dividend Per Share | - | 0.400 | 0.300 | 0.300 | 0.300 | 0.250 | Upgrade
|
| Dividend Growth | - | 33.33% | - | - | 20.00% | - | Upgrade
|
| Gross Margin | 31.66% | 29.74% | 25.30% | 36.35% | 32.58% | 32.31% | Upgrade
|
| Operating Margin | 12.70% | 12.13% | 4.35% | 15.98% | 17.66% | 14.72% | Upgrade
|
| Profit Margin | 8.47% | 7.03% | -1.35% | 11.97% | 11.10% | 7.62% | Upgrade
|
| Free Cash Flow Margin | - | -0.29% | -1.43% | 3.43% | -10.88% | -0.73% | Upgrade
|
| EBITDA | 1,295 | 1,169 | 541.39 | 1,142 | 1,207 | 819.75 | Upgrade
|
| EBITDA Margin | 16.60% | 16.48% | 10.37% | 21.97% | 21.43% | 19.79% | Upgrade
|
| D&A For EBITDA | 304.39 | 308.68 | 314.41 | 311.36 | 212.32 | 210.01 | Upgrade
|
| EBIT | 990.95 | 860.1 | 226.98 | 830.73 | 994.62 | 609.75 | Upgrade
|
| EBIT Margin | 12.70% | 12.13% | 4.35% | 15.98% | 17.66% | 14.72% | Upgrade
|
| Effective Tax Rate | 25.13% | 25.34% | - | 0.98% | 32.54% | 36.40% | Upgrade
|
| Revenue as Reported | 7,868 | 7,137 | 5,270 | 5,251 | 5,666 | 4,171 | Upgrade
|
| Advertising Expenses | - | 15.86 | 8.59 | 4 | 2.18 | 15.62 | Upgrade
|
Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.